Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy


This Phase I/II study will investigate the safety and tolerability of intravitreally administered 0.5mg and 2.0mg Ranibizumab in three monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month of drug safety follow up in subjects with exudative polypoidal choroidal vasculopathy (PCV) for a total of 24 months.

Full Title of Study: “Treatment of Polypoidal Choroidal Vasculopathy With High Dose Ranibizumab (Lucentis): A Phase I Safety Study.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: February 2015

Detailed Description

Twenty eyes will be randomized will receive 3 consecutive monthly intravitreal 2.0 mg/0.5mg (3:1 ratio) Ranibizumab injection with the first injection occuring at Day 0 and second and third injection occuring at month 1 and month 2 respectively. Retreatment with intravitreal Ranibizumab or other therapies will be at the investigators discretion but guidelines for recommended retreatment.


  • Drug: ranibizumab 0.5 or 2.0 mg/0.05 cc
    • ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.

Arms, Groups and Cohorts

  • Experimental: Ranibizumab 2.0 mg
    • Intraocular injection of 2.0 mg/0.05 cc ranibizumab.
  • Active Comparator: Ranibizumab 0.5 mg
    • Intraocular injection of 0.5 mg/0.05 cc ranibizumab.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence and severity of ocular and systemic adverse events will be compared between the 2.0mg and 0.5 mg groups.
    • Time Frame: 2 years
    • Examples include 30 letter loss, major subretinal hemorrhage, involving 75% or more clinical macula (arcade to arcade), disease related vitreous hemorrhage, injection-related endophthalmitis, retinal detachment, vitreous hemorrhage, study drug/procedure – related uveitis, incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs.

Participating in This Clinical Trial

Inclusion Criteria

  • Males and Females >18 years of age. Females of child bearing potential will undergo urine pregnancy testing and be required to use appropriate methods of birth control. – ICG and fluorescein angiographic characteristics consistent with active, leaking PCV with subfoveal lesions and/or subfoveal hemorrhage, lipid exudates, PED or fluid diagnosed within the past 6 months or diagnosed as newly active within the past 6 months. Subjects who completed the 24 month follow up in the original FVF3671s protocol may enter the study without necessarily demonstrating active exudative PCV at enrollment. – Best-Corrected ETDRS Visual Acuity at 4 meters between 20/20 – 20/800. – Lesion size – no limitations. – Lesions Characteristics – leaking lesions consistent with PCV. No limitations on hemorrhage, fibrosis or atrophy. – No therapy (includes non foveal laser, PDT, intravitreal steroids, TTT, radiotherapy, or anti-VEGF therapy) or intraocular surgery within the past 30 days for any condition. – Clear ocular media to allow for photography/angiography. – Ability to provide written informed consent and comply with study assessments for the full duration of the study. Exclusion Criteria:

  • Patients with features of age related macular degeneration such as abundant drusen and demographic features consistent with this diagnosis. – Allergy to Fluorescein, ICG, Iodine, Shellfish. – Pregnancy (positive pregnancy test) – Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated. – Participation in another simultaneous medical investigation or trial. – Exclude other anti-VEGF agents as therapy options. – History of previous subfoveal laser. – Advanced glaucoma (IOP > 25 or cup/disc ration > 0.8) – Any condition in the opinion of the investigator that would interfere with disease status/progression or jeopardize patients' participation in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Southeast Retina Center, Georgia
  • Collaborator
    • Genentech, Inc.
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dennis M. Marcus, M.D., Dr. Dennis M. Marcus Principal Investigator – Southeast Retina Center, Georgia
  • Overall Official(s)
    • Dennis M. Marcus, M.D., Principal Investigator, Southeast Retina Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.